Brain Natriuretic Peptide is Stable for 2 Days at Room Temperature: Implications for Noninvasive Testing of Cardiac Function

1998 ◽  
Vol 94 (s38) ◽  
pp. 6P-6P
Author(s):  
MG Buckley ◽  
NJ Marcus ◽  
MH Yacoub ◽  
DRJ Singer
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Room Temperature ◽  
Noninvasive Testing

Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice

1998 ◽  
Vol 95 (3) ◽  
pp. 235 ◽  
Author(s):  
Martin G. BUCKLEY ◽  
Neil J. MARCUS ◽  
Magdi H. YACOUB ◽  
Donald R.J. SINGER
Keyword(s):  
Clinical Practice ◽  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Non Invasive

BRAIN NATRIURETIC PEPTIDE AS A MARKER OF CARDIAC FUNCTION AFTER ULTRAENDURANCE EXERCISE 700

1996 ◽  
Vol 28 (Supplement) ◽  
pp. 117
Author(s):  
T. Shimomitsu ◽  
H. Iwane ◽  
Y. Odagiri ◽  
T. Katsumura ◽  
T. Hamaoka ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide

Room-Temperature Controllable Synthesis of Hierarchically Flower-like Hollow Covalent Organic Frameworks for Brain Natriuretic Peptide Enrichment

2021 ◽  
Author(s):  
Wen De Ma ◽  
Guorong Li ◽  
Chao Zhong ◽  
Yixin Yang ◽  
Qianqian Sun ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Room Temperature ◽  
Covalent Organic Frameworks ◽  
Controllable Synthesis ◽  
Peptide Enrichment

A facile strategy was introduced for room-temperature controllable synthesis of hierarchically flower-like hollow COFs (FHF-COFs). Furthermore, the universality for synthesis of the HFH-COFs was validated by altering building units. Inspired...

Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction

1999 ◽  
Vol 97 (3) ◽  
pp. 255-258 ◽  
Author(s):  
P. F. DOWNIE ◽  
S. TALWAR ◽  
I. B. SQUIRE ◽  
J. E. DAVIES ◽  
D. B. BARNETT ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Left Ventricular Dysfunction ◽  
Room Temperature ◽  
Ventricular Dysfunction ◽  
Plasma Concentrations ◽  
Left Ventricular ◽  
Blood Samples ◽  
The Stability

Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) are raised in patients with left ventricular dysfunction. Measurement of this peptide has a potential diagnostic role in the identification and assessment of patients with heart failure. The stability of this peptide over time periods and conditions pertaining to routine clinical practice has not been reported previously. Blood samples were obtained from 15 subjects. One aliquot was processed immediately, and the remaining portions of the blood samples were stored for 24 h or 48 h at room temperature or on ice prior to processing. Plasma concentrations of NT-proBNP were measured with a novel immunoluminometric assay developed within our laboratory. Mean plasma concentrations of NT-proBNP were not significantly different whether blood samples were centrifuged immediately and stored at -70 °C or kept at room temperature or on ice for 24 h or 48 h. The mean percentage differences from baseline (reference standard) were +5.2% (95% confidence interval +18.2 to -7.8%) and +0.8% (+15.2 to -13.7%) after storage for 24 h at room temperature or on ice respectively, and +8.9% (+24.2 to -6.5%) and +3.2% (+15.1 to -0.9%) for storage for 48 h at room temperature or on ice respectively. Pearson correlation coefficients for baseline NT-proBNP concentrations compared with levels at 48 h at room temperature or on ice were r = 0.89 and r = 0.83 respectively (both P < 0.0001). Thus NT-proBNP extracted from plasma samples treated with EDTA and aprotinin is stable under conditions relevant to clinical practice.

scholarly journals Circulating N-terminal brain natriuretic peptide and cardiac function in response to acute systemic hypoxia in healthy humans

2014 ◽  
Vol 12 (1) ◽  
pp. 189 ◽  
Author(s):  
Ilkka Heinonen ◽  
Matti Luotolahti ◽  
Olli Vuolteenaho ◽  
Mikko Nikinmaa ◽  
Antti Saraste ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Healthy Humans ◽  
Systemic Hypoxia

Brain Natriuretic Peptide in Hemodialysis Patients: Predictive Value for Hemodynamic Change during Hemodialysis and Cardiac Function

2007 ◽  
Vol 28 (1) ◽  
pp. 122-127 ◽  
Author(s):  
Tetsutaro Matayoshi ◽  
Toako Kato ◽  
Hajime Nakahama ◽  
Hiroto Nakata ◽  
Fumiki Yoshihara ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Predictive Value ◽  
Hemodialysis Patients ◽  
Hemodynamic Change

Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice

1999 ◽  
Vol 97 (6) ◽  
pp. 689-695 ◽  
Author(s):  
Martin G. BUCKLEY ◽  
Neil J. MARCUS ◽  
Magdi H. YACOUB
Keyword(s):  
Clinical Practice ◽  
Cardiac Function ◽  
Natriuretic Peptide ◽  
Room Temperature ◽  
Heart Function ◽  
Routine Clinical Practice ◽  
Blood Samples ◽  
Initial Values ◽  
Significant Difference ◽  
The Stability

Brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal ANP are good research indices of the severity of heart failure. The stability of these peptides at room temperature has become an important factor in assessing their use as indicators of cardiac function in routine clinical practice. Inhibitors such as aprotinin are routinely added in the blood collection process, but may provide no benefit in sample collection and routine clinical practice. We assessed the stability of BNP, ANP and N-terminal ANP in blood samples collected in either the presence or the absence of the protease inhibitor aprotinin. Blood, either with or without aprotinin, was processed immediately (initial; 0 h) and after blood samples had been left for 3 h, 2 days or 3 days at room temperature. These times were chosen to reflect processing in a hospital outpatient clinic (2–3 h), or when posted from general practice (2–3 days). Initial plasma BNP, ANP and N-terminal ANP levels in the absence of aprotinin were 28.2±5.4, 44.2±7.9 and 1997±608 pg/ml respectively, and were not significantly different from initial values in the presence of aprotinin (29.0±5.9, 45.2±8.0 and 2009±579 pg/ml respectively). After 3 h at room temperature, there was a significant fall in ANP in the absence of aprotinin (36.7±7.9 pg/ml; P< 0.005), but not in the presence of aprotinin (41.2±7.6 pg/ml). Both BNP and N-terminal ANP were unchanged in either the absence (BNP, 27.6±5.5 pg/ml; N-terminal ANP, 2099±613 pg/ml) or the presence (BNP, 29.4±5.6 pg/ml; N-terminal ANP, 1988±600 pg/ml) of aprotinin. After 2 days at room temperature, ANP had fallen significantly in both the absence (16.9±3.4 pg/ml) and the presence (24.0±5.0 pg/ml) of aprotinin compared with initial values, and there was a significant difference in ANP levels in the absence and presence of aprotinin (P< 0.001). ANP levels had decreased further after 3 days at room temperature, to 11.9±3.4 pg/ml (no aprotinin) and 20.3±5.0 pg/ml (aprotinin added); these values were significantly different (P = 0.002). In contrast, there was no change in the levels of BNP or N-terminal ANP after 2 or 3 days at room temperature, in either the absence or the presence of aprotinin. These studies indicate that aprotinin adds little benefit to the stability of cardiac peptides at room temperature. Blood samples for BNP and N-terminal ANP measurement used as a test of heart function in hospital clinics and by general practitioners in the community could be taken into blood tubes containing only EDTA as anticoagulant and without the additional step of adding the routinely used inhibitor aprotinin.

Sign in / Sign up

Export Citation Format

Share Document